Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
F. Icli
No relevant relationships to disclose
K. Altundag
No relevant relationships to disclose
U. Coskun
No relevant relationships to disclose
S. Paydas
No relevant relationships to disclose
G. Basaran
No relevant relationships to disclose
P. Saip
No relevant relationships to disclose
G. G. Dogu
No relevant relationships to disclose
Y. Eralp
No relevant relationships to disclose
R. Uslu
No relevant relationships to disclose
A. Sevinc
No relevant relationships to disclose
H. Onur
No relevant relationships to disclose
N. M. Mandel
No relevant relationships to disclose
C. Sezgin
No relevant relationships to disclose
M. Altinbas
No relevant relationships to disclose
N. Guler
No relevant relationships to disclose
A. Isikdogan
No relevant relationships to disclose
E. Gokmen
No relevant relationships to disclose
K. Uygun
No relevant relationships to disclose
Z. Ustuner
No relevant relationships to disclose
A. Yaren
No relevant relationships to disclose